waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.

Basit Öğe Kaydı
dc.authoridSantoro, Armando/0000-0003-1709-9492
dc.authorwosidGlimelius, Ingrid/Q-1325-2015
dc.authorwosidSantoro, Armando/J-9594-2018
dc.contributor.authorZinzani, Pier Luigi
dc.contributor.authorMayer, Jiri
dc.contributor.authorBenjamini, Ohad
dc.contributor.authorBerkovits, Alejandro
dc.contributor.authorGlimelius, Ingrid
dc.contributor.authorStevens, Don A.
dc.contributor.authorChaudhry, Arvind
dc.date.accessioned2024-06-12T11:24:06Z
dc.date.available2024-06-12T11:24:06Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, ILen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipMerck Sharp Dohme Corp.en_US
dc.description.sponsorshipMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26792
dc.identifier.volume41en_US
dc.identifier.wosWOS:001053772005460en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titlewaveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu